Posted on 25/08/2010 in Pharmaceutical Company Product News Bayer Schering Pharma is to enter into collaboration with Cancer Research Technology (CRT) on the development of an innovative new treatment approach.
The agreement will see the two organisations evaluate new leptin antagonist peptides developed by the Boston Biomedical Research Institute (BBRI) as potential experimental treatments, focusing on the fields of gynaecological and oncological diseases.
It is thought that the protein leptin, which triggers growth in different types of cells such as endometrial cells, plays a role in the development of several conditions.
Bayer Schering Pharma will evaluate the ability of the peptides to switch off the activity of leptin, with an option for a licence agreement for the technology having been agreed.
Larry Steranka, managing director of CRT, said: "We're delighted to have worked alongside BBRI to partner its technology with the right commercial partner to take forward the development of potential new treatments."
Earlier this month, Bayer Schering Pharma published data from a clinical trial of its new oral therapy rivaroxaban, demonstrating its efficacy against deep vein thrombosis. Other news stories from 25/08/2010
Read more in the Zenopa News Archive
How this news is generated
|
